Independent healthcare equity research
Clarity in the healthcare markets.
Fundamental research and analysis on the companies shaping medicine, biotech, and life sciences.
Fundamental research and analysis on the companies shaping medicine, biotech, and life sciences.
Meili Capital is an independent equity research practice dedicated entirely to the healthcare and life sciences sector. The premise is simple: depth beats breadth. By covering one sector closely, the research can engage with the things that actually move these companies — clinical trial data, regulatory pathways, reimbursement, and competitive pipelines.
Every note begins with the fundamentals: the underlying business, the science behind it, the addressable market, and the financials that tie it together.
The aim is to cut through the noise around a sector that is famously complex and headline-driven, and to write the kind of clear, reasoned analysis that helps readers form their own view.
This is a publication, not an advisory service. Everything here is research and commentary — a way of thinking out loud about an industry worth understanding deeply.
Bottom-up analysis of the business, the science, and the balance sheet — not the ticker.
One industry, studied closely: pharma, biotech, med-tech, and the systems around them.
Clear write-ups that show the working, so you can judge the argument for yourself.
These are placeholder entries to show the layout — replace them with your own research notes as you publish.
For questions, feedback on the research, or to follow new notes as they publish — reach out directly. I read everything.